




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61B 5/00		A2	(11) International Publication Number: WO 99/60920
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11672		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 May 1999 (26.05.99)			
(30) Priority Data: 60/086,817 26 May 1998 (26.05.98) US 09/105,033 25 June 1998 (25.06.98) US			
(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; P.O. Box 7365, Madison, WI 53707-7365 (US).			
(72) Inventors: FRAYNE, Richard; 3712 Hillcrest Drive, Madison, WI 53705-5240 (US). STROTHER, Charles, M.; 6014 Greentree Road, Madison, WI 53711 (US). UNAL, Orhan; 3005 Prairie Road, Madison, WI 53719 (US). YANG, Zhihao; 305 H Eagle Height, Madison, WI 53705 (US). WEHELIE, Abukar; 230 Randolph Drive, 102C, Madison, WI 53717 (US). YU, Hyuk; 3183 Danhouser Road, Blue Mounds, WI 53517 (US).		Published Without international search report and to be republished upon receipt of that report.	
(74) Agents: WELCH, Teresa, J. et al.; Michael Best & Friedrich, LLP, Suite 700, One South Pinckney Street, Madison, WI 53701-1806 (US).			

(54) Title: MR SIGNAL-EMITTING COATINGS



(57) Abstract

The present invention provides a coating that emits magnetic resonance signals and a method for coating medical devices therewith. The coating includes a paramagnetic metal ion-containing polymer complex that facilitates diagnostic and therapeutic techniques by readily visualizing medical devices coated with the complex.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MR SIGNAL-EMITTING COATINGS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the priority date under 35 U.S.C. §119 of U.S. Provisional Application No. 60/086817, filed May 26, 1998.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government support under Grant Nos. NIH 1 ROI HL57983; NIH 1 R29 HL57501 awarded by the National Institutes of Health, and NSF-DMR 9711226 and NSF-EEC 8721845(ERC) awarded by the National Science Foundation. The U.S. Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

This invention relates generally to coatings that emit magnetic resonance signals and in particular, to such coatings containing paramagnetic metal ions, and to a process for coating medical devices with such coatings so that the devices are readily visualized in magnetic resonance images during diagnostic or therapeutic procedures done in conjunction with magnetic resonance imaging (MRI).

Since its introduction, magnetic resonance (MR) has been used to a large extent solely for diagnostic applications. With advancement of magnetic resonance imaging, however, it is becoming possible to replace many diagnostic x-ray imaging applications with MR techniques. For example, the accepted standard for staging vascular disease was, at one

time, x-ray contrast angiography. Today, MR angiographic techniques are being increasingly used to detect vascular abnormalities and, in some specific clinical instances, contrast-enhanced MR angiograms are rapidly approaching the diagnostic standard set by x-ray angiography.

5 More recently, advances in MR hardware and imaging sequences have begun to permit the use of MR in certain therapeutic procedures. That is, certain therapeutic procedures or therapies are performed on a patient while the patient and the instruments, devices or agents used and/or implanted are being imaged. The use of MR in this manner of
10 image-guided therapy is often referred to as interventional magnetic resonance (interventional MR). These early applications have included: monitoring ultrasound and laser ablations, guiding the placement of biopsy needles, and visualizing disease, such as tumors, intraoperatively.

Of particular interest in interventional MR is endovascular therapy.
15 Endovascular therapy refers to a general class of minimally-invasive interventional (or surgical) techniques which are used to treat vascular abnormalities. Unlike conventional surgical techniques, endovascular therapies access and treat the disease from within the vasculature. The vascular system is usually accessed via the femoral artery. A small
20 incision is made in the groin and the femoral artery punctured. A sheath is then inserted for vascular access. A catheter with the addition of a guide-wire can then be manipulated under fluoroscopic guidance to the area of interest. The guide-wire is then removed from the catheter lumen, and either a therapeutic device (e.g., balloon, stent, coil) is
25 inserted with the appropriate delivery device, or an agent (e.g., embolizing agent, anti-vasospasm agent) is injected through the catheter. In either instance, the catheter functions as a conduit and ensures the accurate and localized delivery of the therapeutic device or agent. Once the device or agent is in place, its delivery system is withdrawn, i.e., the

catheter is withdrawn, the sheath removed and the incision closed. The duration of an average endovascular procedure is about 3 hours, although difficult cases may take more than 8 hours. Traditionally, such procedures have been performed under x-ray fluoroscopic guidance.

5 Performance of these procedures under MR-guidance provides a number of advantages. Safety issues are associated with the relatively large dosages of ionizing radiation required in x-ray fluoroscopy. While radiation risk to the patient is of somewhat less concern (since it is more than offset by the potential benefit of the procedure), exposure to the
10 interventional staff can be a major problem. In addition, the complication rate from MR contrast agents is much less than the commonly used iodinated x-ray contrast agents.

 Other advantages of MR-guided procedures include the ability of MR to acquire three-dimensional images. In contrast, most x-ray
15 angiography systems can only acquire a series of projection images. MR has clear advantages when multiple projections or volume reformatting are required in order to understand the treatment of complex three-dimensional vascular abnormalities, such as arterial-venous malformations (AVMs) and aneurysms. Furthermore, MR is sensitive to
20 a variety of "functional" parameters including temperature, blood flow, tissue perfusion, diffusion and brain activation. This additional diagnostic information, which, in principle, may be obtained before, during and immediately after therapy, cannot be acquired by x-ray fluoroscopy alone. It is likely that once suitable MR-based endovascular
25 procedures have been developed, the next challenge will be to integrate this functional information with conventional anatomical imaging and device tracking.

Currently, both "active" and "passive" approaches are being used to monitor the placement of interventional devices under MR guidance. With active tracking, visualization is accomplished by incorporating one or more small radio-frequency (RF) coils into the device, e.g., a catheter. 5 The position of the device is computed from MR signals detected by the coil. Later, this information is superimposed on a previously acquired anatomical "road map" image. The advantages of active tracking include excellent temporal resolution and spatial accuracy, and the ease with which the tip position, e.g., of a catheter, can be updated at 20 Hz, i.e., 10 20 times per second.

However, active methods allow visualization of only a discrete point(s) on the device. Typically, only the tip of the device is "active", i.e., visualized. Although it is possible to incorporate multiple RF coils (4-6 on typical clinical MR systems) into a device, it is still impossible to 15 determine position at more than a few discrete points along the device. While this may be acceptable for tracking rigid biopsy needles, this is a significant limitation for tracking flexible devices as in endovascular therapy. Furthermore, intravascular heating due to RF-induced currents is a concern with active methods.

20 As noted above, the attachment of coils onto flexible catheters present numerous challenges. Also, the effect on the mechanical properties of catheters is of concern. Ladd et al. (Ladd et al., *Proc. ISMRM* (1997) 1937) have addressed some of the deficiencies of an active catheter by designing an RF coil that wraps about the catheter. 25 This allows visualization of a considerable length of a catheter, but still does not address the problems of RF heating and mechanical catheter performance.

Passive tracking technologies use the fact that endovascular devices do not generally emit a detectable MR signal and, thus, result in

areas of signal loss or signal voids in MR images. Such signal loss, for example, occurs with a polyethylene catheter. By following the void, the motion of the catheter can be inferred. One advantage of passive tracking methods over active methods is that they do allow
5 "visualization" of the entire length of a device. Signal voids, however, are certainly not optimal for device tracking because they can be confused with other sources of signal loss.


A further source of passive contrast occurs if the device has a magnetic susceptibility much different than tissue (e.g., metallic guide-
10 wires and stents). Susceptibility differences cause local distortions to the magnetic field and result in regions of signal enhancement and of signal loss surrounding the device. A number of published reports describe passive catheter visualization schemes based on signal voids or susceptibility-induced artifacts. A principal drawback of the currently
15 available passive techniques is that visualization is dependent on the orientation of the device with respect to the main magnetic field.

Despite recognition and study of various aspects of the problems of visualization of medical devices in therapeutic, especially endovascular, procedures, the prior art has still not produced satisfactory
20 and reliable techniques for visualization and tracking of the entire device in a procedure under MR guidance.

BRIEF SUMMARY OF THE INVENTION

The present invention provides a process for coating medical devices so that the devices are readily visualized, particularly, in T-1
25 weighted magnetic resonance images. Because of the high signal caused by the coating, the entirety of the coated devices can be readily visualized during, e.g., an endovascular procedure.

The foregoing, and other advantages of the present invention, are realized thereof in a magnetic resonance (MR) signal-emitting coating which includes a paramagnetic metal ion-containing polymer complex and a method of visualizing medical devices in magnetic resonance
5 imaging, which includes the step of coating the devices with the paramagnetic-ion containing polymer. Specifically, the present invention provides a coating for visualizing medical devices in magnetic resonance imaging, comprising a complex of formula (I):



10 wherein P is a polymer, X is a surface functional group, L is a chelate, M is a paramagnetic ion and n is an integer that is 2 or greater.

In another aspect, the invention is a coating for visualizing medical devices in magnetic resonance imaging, comprising a complex of formula (II):



wherein P is a polymer, X is a surface functional group, L is a chelate, M is a paramagnetic ion, n is an integer that is 2 or greater and J is the linker or spacer molecule.

In a further aspect, the invention is a magnetic resonance imaging
20 system which includes a magnetic resonance device for generating a magnetic resonance image of a target object (as defined hereinafter) in an imaging region (as defined hereinafter) and an instrument for use with the target object in the imaging region. The instrument includes a body sized for use in the target object and a polymeric-paramagnetic ion
25 complex coating in which the complex is represented by formula (I):



wherein P is a polymer, X is a surface functional group, L is a chelate, M is a paramagnetic ion and n is an integer that is 2 or greater.

In yet another aspect, the invention is a method for visualizing medical devices in magnetic resonance imaging which includes the steps of (a) coating the medical device with a polymeric-paramagnetic complex of formula (I):



wherein P is a polymer, X is a surface functional group, L is a chelate, M is a paramagnetic ion and n is an integer that is 2 or greater; (b) positioning the device within a target object; and (c) imaging the target object and coated device.

10 Other advantages and a fuller appreciation of the specific attributes of this invention will be gained upon an examination of the following drawings, detailed description of preferred embodiments, and appended claims. It is expressly understood that the drawings are for the purpose of illustration and description only, and are not intended as a definition
15 of the limits of the invention.

BRIEF DESCRIPTION OF THE DRAWING(S)

The preferred exemplary embodiment of the present invention will hereinafter be described in conjunction with the appended drawing wherein like designations refer to like elements throughout and in which:

20 Figure 1 is a schematic representation of the three-step coating method in accordance with the present invention;

Figure 2 is a schematic representation of the four-step coating method using a linker agent;

Figures 3 and 3A are a schematic representation of a plasma
25 reactor for use in the method of the present invention, Figure 3A being an enlarged view of the vapor supply assemblage of the plasma reactor of Figure 3;

Figure 4 is several MR images of coated devices in accordance with the present invention;

Figure 5 is temporal MR snapshots of a Gd-DTPA-filled catheter;

Figure 6 is temporal MR snapshots of a Gd-DTPA-filled catheter
5 moving in the common carotid of a canine; and

Figure 7 is temporal MR snapshots of a Gd-DTPA-filled catheter in a canine aorta.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates broadly to coating substances that
10 are capable of emitting magnetic resonance signals. The present invention is most particularly adapted for use in coating medical devices so that they are readily visualized in magnetic resonance images. Accordingly, the present invention will now be described in detail with respect to such endeavors; however, those skilled in the art will
15 appreciate that such a description of the invention is meant to be exemplary only and should not be viewed as limitative on the full scope thereof.

The present invention provides coatings containing paramagnetic ions. The coatings of the present invention are characterized by an
20 ability to emit magnetic resonance signals and to permit visualization of the entirety of a device or instrument so coated in interventional MR procedures. The coatings are also of value for providing improved visibility in interoperative MR of surgical instruments after being coated with the signal-enhancing coatings of the present invention. It is also
25 anticipated that the improved visualization of implanted devices so coated, e.g., stents, may find a whole host of applications in diagnostic MR. These attributes of the coating in accordance with the present

invention are achieved through a novel combination of physical properties and chemical functionalities.

In the following description of the method of the invention, process steps are carried out at room temperature (RT) and atmospheric pressure unless otherwise specified.

Throughout the specification, the term "medical device" is used in a broad sense to refer to any tool, instrument or other object (e.g., a catheter, biopsy needle, etc.) employed to perform or useful in performing an operation on a target, or a device which itself is implanted in the body (human or animal) for some therapeutic purpose, e.g., a stent, a graft, etc., and a "target" or "target object" being all or part of a human patient or animal positioned in the "imaging region" of a magnetic resonance imaging system (the "imaging region" being the space within an MRI system in which a target can be imaged).

Of particular interest are endovascular procedures performed under MR guidance. Such endovascular procedures include the treatment of partial vascular occlusions with balloons, arterial-venous malformations with embolic agents, aneurysms with stents or coils, as well as sub-arachnoid hemorrhage (SAH)-induced vasospasm with local applications of papaverine. In these therapeutic procedures, the device or agent is delivered via the lumen of a catheter, the placement of which has traditionally relied on, to varying degrees, x-ray fluoroscopic guidance.


In one aspect, the present invention provides a method of coating the surface of medical devices with a coating which is a polymeric material containing a paramagnetic ion, which coating is generally represented by formula (I):



wherein P is a polymer, X is a surface functional group such as an amino or a carboxyl group, L is a chelate, M is a paramagnetic ion which binds

to L, and n is an integer that is 2 or greater. It is understood that a medical device may be suitably constructed of a polymer whose surface is then functionalized with X, or a medical device may be suitably coated with a polymer whose surface is then suitably functionalized. Such methods for coating are generally known in the art.

To enhance the rotational mobility of M^{n+} , the coating optionally contains a linker or spacer molecule J, and is generally represented by the formula (II):



wherein P, X, L and M are as described above and J is the linker or spacer molecule which joins the surface functional group X and the chelate L, i.e., J is an intermediary between the surface functional group and the chelate.

P is suitably any polymer including but not limited to polyethylene, polypropylene, polyesters, polycarbonates, polyamides such as nylon, polytetrafluoroethylene (TeflonTM) and polyurethanes that can be surface functionalized with an X group. It is noted that some polymer surfaces may need to be coated further with hydrophilic layers. J is suitably a bifunctional molecule, e.g., a lactam having an available amino group and a carboxyl group, an α,ω -diamine having two available amino groups or a fatty acid anhydride having two available carboxyl groups. X is suitably an amino or carboxyl group. L is suitably any chelate which has a relatively high (e.g., $>10^{20}$) stability constant, K, for the chelate-paramagnetic ion complex. Such chelates include but are not limited to diethylene triamine pentaacetic acid (DTPA), tetraazacyclododecane tetraacetic acid (DOTA) and tetraazacyclo tetradecane tetraacetic acid (TETA). The paramagnetic ion is suitably a multivalent paramagnetic metal including but not limited to the lanthanides and transition metals such as iron, manganese, chromium, cobalt and nickel. Preferably, M^{n+}

is a lanthanide which is highly paramagnetic, most preferred of which is the gadolinium(III) ion having seven unpaired electrons in the 4f orbital.

It is noted that the gadolinium(III) (Gd (III)) ion is often used in MR contrast agents, i.e., signal influencing or enhancing agents, because it is highly paramagnetic having a large magnetic moment due to the seven unpaired 4f orbital electrons. In such contrast agents, gadolinium is generally combined with a chelating agent, such as DTPA. The resulting complex (Gd-DTPA or Magnevist; Berlex Imaging, Wayne, New Jersey) is very stable *in vivo*, and has a formation constant of $> 10^{23}$, making it safe for human use. Similar agents have been developed by chelating the gadolinium ion with other complexes, e.g., MS-325, Epix Medical, Cambridge, Massachusetts. The gadolinium (III) causes a localized T-1 reduction in the protons in its environment, giving enhanced visibility in T-1 weighed MR images.

The MR signal-emitting coatings in accordance with the present invention are synthesized according to a three or four-step process. The three-step method includes: (i) plasma-treating the surface of a polymeric material (or a material coated with a polymer) to yield surface functional groups, e.g., using a nitrogen-containing gas or vapor such as hydrazine (NH_2NH_2) to yield amino groups ; (ii) binding a chelating agent, e.g., DTPA, to the surface functional group; and (iii) coordinating a functional paramagnetic metal ion such as Gd(III) with the chelating agent. It is noted that the linkage between the surface functional groups and the chelates is often an amide-type linkage. In addition to hydrazine, other plasma gases which can be used to provide surface functional amino groups include urea, ammonia, a nitrogen-hydrogen combination or combinations of these gases. Plasma gases which provide surface functional carboxyl groups include carbon dioxide or oxygen.

A schematic reaction process of a preferred embodiment of the present invention is shown in Figure 1. As seen specifically in Figure 1, polyethylene is treated with a hydrazine plasma to yield surface functionalized amino groups. The amino groups are reacted with DTPA
5 in the presence of a coupling catalyst, e.g., 1,1'-carbonyldiimidazole, to effect an amide linkage between amino groups and DTPA. The surface amino-DTPA groups are then treated with gadolinium (III) chloride, coordinating the gadolinium (III) ion with the DTPA.

To enhance the rotational component of the interaction of the
10 paramagnetic ion with the environmental water, the MR-signal-emitting coatings are suitably made via a four-step process which is similar to the three-step process except that prior to step (ii), i.e., prior to reaction with the chelating agent, a linker agent or spacer molecule, e.g., a lactam, is bound to the surface functional groups, resulting in the coating of
15 formula (II).

An illustrative schematic reaction process using a lactam is shown in Figure 2. As seen in Figure 2, a polyethylene with an amino functionalized surface is reacted with a lactam. The amino groups and lactam molecules are coupled via an amide linkage. It is noted that "m"
20 in the designation of the amino-lactam linkage is suitably an integer greater than 1. The polyethylene-amino-lactam complex is then reacted with DTPA which forms a second amide linkage at the distal end of the lactam molecule. The last step in the process, coordinating the gadolinium (III) ion with the DTPA (not shown in Figure 2), is the same
25 as shown in Figure 1.

Specific reaction conditions for forming a coating in accordance with the present invention, which utilizes surface functionalized amino groups, include plasma treatment of a polymeric surface, e.g., a polyethylene surface, at 50 W power input in a hydrazine atmosphere

within a plasma chamber, schematically represented in Figure 3, for 5-6 min. at 13 Pa to 106 Pa (100 mT-800 mT).

As seen in Figure 3, an exemplary plasma chamber, designated generally by reference numeral 20, includes a cylindrical stainless steel reaction chamber 22 suitably having a 20 cm diameter, a lower electrode 24, which is grounded, and an upper electrode 26, both suitably constructed of stainless steel. Electrodes 24 and 26 are suitably 0.8 cm thick. Upper electrode 26 is connected to an RF-power supply (not shown). Both electrodes are removable which facilitates post-plasma cleaning operations. Lower electrode 24 also forms part of a vacuum line 28 through a supporting conical-shaped and circularly-perforated stainless steel tubing 30 that has a control valve 31. The evacuation of chamber 22 is performed uniformly through a narrow gap (3 mm) existing between lower electrode 24 and the bottom of chamber 22. Upper electrode 26 is directly connected to a threaded end of a vacuum-tight metal/ceramic feedthrough 32 which assures both the insulation of the RF-power line from the reactor and the dissipation of the RF-power to the electrodes. A space 34 between upper electrode 26 and the upper wall of chamber 22 is occupied by three removable 1 cm thick, 20 cm diameter PyrexTM glass disks 36. Disks 36 insulate upper electrode 26 from the stainless steel top of the reactor 20 and allow the adjustment of the electrode gap. The reactor volume located outside the perimeter of the electrodes is occupied by two PyrexTM glass cylinders 38 provided with four symmetrically located through-holes 40 for diagnostic purposes.

This reactor configuration substantially eliminates the non-plasma zones of the gas environment and considerably reduces the radial diffusion of the plasma species, consequently leading to more uniform plasma exposure of the substrates (electrodes). As a result, uniform

surface treatment and deposition processes (6-10% film thickness variation) can be achieved.

The removable top part of the reactor 20 vacuum seals chamber 22 with the aid of a copper gasket and fastening bolts 42. This part of the reactor also accommodates a narrow circular gas-mixing chamber 44 provided with a shower-type 0.5 mm diameter orifice system, and a gas- and monomer supply connection 46. This gas supply configuration assures a uniform penetration and flow of gases and vapors through the reaction zone. The entire reactor 20 is thermostated by electric heaters attached to the outside surface of chamber 22 and embedded in an aluminum sheet 48 protecting a glass-wool blanket 50 to avoid extensive loss of thermal energy.

For diagnostic purposes, four symmetrically positioned stainless steel port hole tubings 51 are connected and welded through insulating blanket 50 to the reactor wall. These port holes are provided with exchangeable, optically smooth, quartz windows 52. A vapor supply assemblage 54, as seen in Figure 3A, includes a plasma reservoir 56, valves 58, VCR connectors 60 and connecting stainless steel tubing 62. Assemblage 54 is embedded in two 1cm thick copper jackets 64 provided with controlled electric heaters to process low volatility chemicals. Assemblage 54 is insulated using a glass-wool blanket coating. The thermostatic capabilities of reactor 20 are in the range of 25-250°C.

Once the device to be coated is surface functionalized, it is then immersed in a solution of the chelating agent, e.g., DTPA, in, e.g., anhydrous pyridine, typically with a coupling catalyst, e.g., 1,1'-carbonyldiimidazole, for a time sufficient for the chelate to react with the amine groups, e.g., 20 hours. The surface is washed sequentially with solvents, e.g., pyridine, chloroform, methanol and

water. The chelate-treated surface is then soaked in a solution of a salt of the paramagnetic ion, e.g., $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ in water, for a time sufficient for the paramagnetic ion to react with the chelate, e.g., 12 hours. The surface is then washed with water.

5 In test processes, each step has been verified to confirm that the bonding, in fact, occurs. To verify the amino group functionalization, x-ray photoelectron spectroscopy (XPS) was used. A XPS spectrum of the polyethylene surface was taken prior to and after plasma treatment. The XPS spectrum of polyethylene before the treatment showed no nitrogen
10 peak. After treatment, the nitrogen peak was 5.2% relative to carbon and oxygen peaks of 63.2% and 31.6%, respectively.

To determine whether the amino groups were accessible for chemical reactions, after step (i) the surface was reacted with p-fluorophenone propionic acid and rinsed with solvent (tetrahydrofuran).
15 This reactant, chosen because of good sensitivity of fluorine atoms to XPS, produces many photoelectrons upon x-ray excitation. The result of the XPS experiment showed a significant fluorine signal. The peaks for fluorine, nitrogen, carbon and oxygen were: 3.2%, 1.5%, 75.7% and 19.6%, respectively. This demonstrated that the amino groups
20 were accessible and capable of chemical reaction.

Because the coatings in accordance with the present invention are advantageously applied to catheters and because a catheter surface is cylindrical, it is noted that to coat commercial catheters, the plasma reaction must be carried out by rotating the catheter axis normal to the
25 plasma sheath propagation direction. Such rotational devices are known and can be readily used in the plasma reactor depicted in Figure 3. To verify that surface amination occurs for such surfaces, atomic force spectroscopy (AFM) is used to study the surface morphology because XPS requires a well-defined planar surface relative to the incident X-ray

beam. Once coated, the coating densities (e.g., nmol $\text{Gd}^{3+}/\text{m}^2$) are measured using NMR and optimal coating densities can be determined.

It is also understood that metallic surfaces can be treated with the coatings in accordance with the present invention. Metallic surfaces, e.g., guide-wires, can be coated with polymer, e.g., polyethylene, by various known surface-coating techniques, e.g., melt coating, a well known procedure to overcoat polymers on metal surfaces. Once the metallic surfaces are overcoated with polymer, all other chemical steps as described herein apply.

The present invention is further explained by the following examples which should not be construed by way of limiting the scope of the present invention.

Example 1: Preparation of coated polyethylene sheets

Polyethylene sheets were coated in the three-step process described herein.

Surface Amination. A polyethylene sheet (4.5 in diameter and 1 mil thick) was placed in a capacitively coupled, 50 kHz, stainless steel plasma reactor (as shown schematically in Figures 3 and 3A) and hydrazine plasma treatment of the polyethylene film was performed. The substrate film was placed on the lower electrode. First, the base pressure was established in the reactor. Then, the hydrazine pressure was slowly raised by opening the valve to the liquid hydrazine reservoir. The following plasma conditions were used: base pressure = 60 mT; treatment hydrazine pressure = 350 mT; RF Power = 25 W; treatment time = 5 min; source temperature (hydrazine reservoir) = 60°C; temperature of substrate = 40°C. Surface atomic composition of untreated and plasma-treated surfaces were evaluated using XPS (Perkin-Elmer Phi-5400; 300 W power; Mg source; 15 kV; 45° angle).

DTPA Coating. In a 25 mL dry flask, 21.5 mg of DTPA was added to 8 mL of anhydrous pyridine. In a small vessel, 8.9 mg of carbonyldiimidazole (CDI), as a coupling catalyst, was dissolved in 2 mL of anhydrous pyridine. The CDI solution was slowly added into the reaction flask while stirring, and the mixture was stirred at room temperature for 2 hours. The solution was then poured into a dry Petri dish, and the hydrazine-plasma treated polyethylene film was immersed in the solution. The Petri dish was sealed in a desiccator after being purged with dry argon for 10 min. After reaction for 20 hours, the polyethylene film was carefully washed in sequence with pyridine, chloroform, methanol and water. The surface was checked with XPS, and the results showed the presence of carboxyl groups, which demonstrate the presence of DTPA.

Gadolinium (III) Coordination. 0.70 g of $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$ was dissolved in 100 mL of water. The DTPA-treated polyethylene film was soaked in the solution for 12 hr. The film was washed with water. The surface was checked with XPS and showed two peaks at a binding energy (BE) = 153.4 eV and BE = 148.0 eV, corresponding to chelated Gd^{3+} and free Gd^{3+} , respectively. The film was repeatedly washed with water until the free Gd^{3+} peak at 148.0 eV disappeared from the XPS spectrum.

The results of the treatment in terms of relative surface atomic concentration are given below in Table 1.

Table 1
Relative Surface Atomic concentration of
untreated and treated PE surfaces

	<u>% Gd</u>	<u>% N</u>	<u>% O</u>	<u>% C</u>
Untreated PE	0.0	0.0	2.6	97.4
Hydrazine plasma treated PE	0.0	15.3	14.5	70.2
DTPA coated PE	0.0	5.0	37.8	57.2
Gd coated PE	1.1	3.7	35.0	60.3

Example 2: Preparation of coated polyethylene sheets including linker agent

Coated polyethylene sheets are prepared according to the method of Example 1, except that after surface amination, the polyethylene sheet is reacted with a lactam, and the sheet washed before proceeding to the chelation step. The surface of the film is checked for amine groups using XPS.

Example 3: Imaging of coated polyethylene and polypropylene sheets

MR signal enhancement was assessed by imaging coated sheets of polyethylene and polypropylene, prepared as described in Example 1, with gradient-recalled echo (GRE) and spin-echo (SE) techniques on a clinical 1.5 T scanner. The sheets were held stationary in a beaker filled with a tissue-mimic, yogurt, and the contrast-enhancement of the coating was calculated by normalizing the signal near the sheet by the yogurt signal. The T1-weighted GRE and SE MR images showed signal enhancement near the coated polymer sheet. The T1 estimates near the coated surface and in the yogurt were 0.4 s and 1.1 s, respectively. No enhancement was observed near control sheets. The MR images acquired are shown in Figure 4.

Example 4: *In vitro* testing of Gd-DTPA filled catheter visualization

The following examples demonstrated the utility of Gd-DTPA in visualizing a catheter under MR guidance.

A Gd-DTPA-filled single lumen catheter 3-6 French (1-2 mm) was imaged in an acrylic phantom using a conventional MR Scanner (1.5T Signa, General Electric Medical Systems) while it was moved manually

by discrete intervals over a predetermined distance in either the readout direction or the phase encoding direction. The phantom consisted of a block of acrylic into which a series of channels had been drilled. The setup permitted determination of the tip position of the catheter with an accuracy of ± 1 mm (root-mean-square). Snapshots of the catheter are shown in Figure 5.

Example 5: *In vivo* testing of Gd-DTPA-filled catheter visualization

For *in vivo* evaluation, commercially-available single lumen catheters filled with Gd-DTPA (4-6% solution), ranging in size between 3 and 6 French (1-2 mm), and catheter/guide-wire combinations were imaged either in the aorta or in the carotid artery of four canines. All animal experiments were conducted in conjunction with institution-approved protocols and were carried out with the animals under general anesthesia. The lumen of the catheter is open at one end and closed at the other end by a stopcock. This keeps the Gd-DTPA solution in the catheter. The possibility of Gd-DTPA leaking out of the catheter lumen through the open end was small and is considered safe because the Gd-DTPA used in these experiments is commercially available and approved for use in MR. Reconstructed images made during catheter tracking were superimposed on previously acquired angiographic "roadmap" images typically acquired using a 3D TRICKS imaging sequence (F.R. Korosec, R. Frayne, T.M. Grist, C.A. Mistretta, *36 Magn. Reson. Medicine*. (1996) 345-351, incorporated herein by reference) in conjunction with either an intravenous or intra-arterial injection of Gd-DTPA (0.1 mmol/kg). On some occasions, subtraction techniques were used to eliminate the background signal from the catheter images prior to superimposing them onto a roadmap image. Snapshots of the canine carotids and aortas are shown in Figures 6 and 7, respectively.

Example 6: *In vivo* catheter MR visualization

Using canines, a catheter coated with a coating in accordance with the present invention/guide-wire combination is initially positioned in the femoral artery. Under MR guidance, the catheter is moved first to the aorta, then to the carotid artery, then to the circle of Willis, and on to the middle cerebral artery. The catheter movement is clearly seen in the vessels. The length of time to perform this procedure and the smallest vessel successfully negotiated is recorded.

Example 7: Paramagnetic ion safety testing

A gadolinium leaching test is performed to ascertain the stability of the Gd-DTPA complex. Polyethylene sheets coated with a coating in accordance with the present invention are subjected to simulated blood plasma buffers and blood plasma itself. NMR scans are taken and distinguish between chelated Gd^{3+} and free Gd^{3+} . The results indicate that the Gd^{3+} complex is stable under simulated blood conditions.

Example 8: Biocompatibility testing

A biocompatibility test is carried out on polymeric surfaces coated in accordance with the present invention using an adsorption method of serum albumin labeled with fluorescent dyes. If the albumin is irreversibly adsorbed as detected by fluorescence of coated catheter surfaces, the coat is adjudged to be bioincompatible.

Example 9: Determination of coating signal intensities

A clinical 1.5 T scanner (Signa, General Electric Medical Systems) is used to determine the optimal range of coating densities (in mmol Gd^{3+} m^{-2}) for producing appreciable signal enhancement on a series of

silicon wafers coated with a polyethylene-Gd-containing coating in accordance with the present invention. The wafers are placed in a water bath and scanned cross-sectionally using a moderately high-resolution fast gradient-recalled echo (FGRE) sequence with $TR \approx 7.5$ ms/ $TE \approx 1.5$ ms, 256 X 256 acquisition matrix and a 16 cm X 16 cm field-of-view (FOV). The flip angle is varied from 10° to 90° in 10° increments for each coating density. A region of interest (ROI) is placed in the water adjacent to the wafer and the absolute signal is calculated.

For calibration of signal measurements obtained in different imaging experiments, a series of ten calibration vials is also imaged. The vials contain various concentrations of Gd-DTPA, ranging from 0 mmol mL^{-1} to 0.5 mmol mL^{-1} . This range of concentrations corresponds to a range of T1 relaxation times (from < 10 ms to 1000 ms) and a range of T2 relaxation times. The signals in each vial are also measured and used to normalize the signals obtained near the wafers. Normalization corrections for effects due to different prescan settings between acquisitions and variable image scaling are applied by the scanner. A range of concentrations in the vials facilitates piece-wise normalization. An optimal range of coating densities is determined.

In summary, the present invention provides a method of visualizing medical devices under MR guidance utilizing a coating, which is a polymeric-paramagnetic ion complex, on the medical devices.

While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions, that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that can lawfully be accorded the appended claims.

CLAIM(S)

What is claimed is:

1. A magnetic resonance imaging system, comprising:
a magnetic resonance device for generating a magnetic resonance
5 image of a target object in an imaging region; and
an instrument for use with the target object in the imaging region,
said instrument including a body sized for use in the target object and a
polymeric-paramagnetic ion complex coating thereon in which said
complex is represented by formula (I):



wherein P is a polymer, X is a surface functional group, L is a chelate,
M is a paramagnetic ion and n is an integer that is 2 or greater.

2. The system of claim 1, wherein P is selected from the group
consisting of polyethylene, polypropylene, polyesters, polyamides,
15 polyfluoroethylene and polyurethanes.

3. The system of claim 1, wherein X is an amino group or a
carboxyl group.

4. The system of claim 1, wherein M is a lanthanide or a
transition metal which is iron, manganese, chromium, cobalt or nickel.

- 20 5. A coating for visualizing medical devices in magnetic
resonance imaging, comprising a complex of formula (I):



wherein P is a polymer, X is a surface functional group, L is a chelate,
M is a paramagnetic ion and n is an integer that is 2 or greater.


6. The coating of claim 5, wherein P is selected from the group consisting of polyethylene, polypropylene, polyesters, polyamides, polyfluoroethylene and polyurethanes.

7. The coating of claim 5, wherein X is an amino group or a
5 carboxyl group.

8. The coating of claim 5, wherein M is a lanthanide or is a transition metal which is iron, manganese, chromium, cobalt or nickel.

9. A coating for visualizing medical devices in magnetic resonance imaging, comprising a complex of formula (II):

10



wherein P is a polymer, X is a surface functional group, L is a chelate, M is a paramagnetic ion, n is an integer that is 2 or greater and J is the linker or spacer molecule.

10. The coating of claim 9, wherein P is selected from the group
15 consisting of polyethylene, polypropylene, polyesters, polyamides, polyfluoroethylene and polyurethanes.

11. The coating of claim 9, wherein X is an amino group or a carboxyl group.

12. The coating of claim 9, wherein M is a lanthanide or is a
20 transition metal which is iron, manganese, chromium, cobalt or nickel.

13. The coating of claim 9, wherein J is a lactam.

14. A method for visualizing medical devices in magnetic resonance imaging, comprising:

- (a) coating the medical device with a polymeric-paramagnetic complex of formula (I):



wherein P is a polymer, X is a surface functional group, L is a chelate, M is a paramagnetic ion and n is an integer that is 2 or greater.

- (b) positioning the device within a target object; and
10 (c) imaging the target object and coated device.

15. The method of claim 14, wherein P is selected from the group consisting of polyethylene, polypropylene, polyesters, polyamides, polyfluoroethylene and polyurethanes.

16. The method of claim 14, wherein X is an amino group or a
15 carboxyl group.

17. The method of claim 14, wherein M is a lanthanide or is a transition metal which is iron, manganese, chromium, cobalt or nickel.

18. An magnetic resonance (MR)-emitting coating, comprising a paramagnetic ion-containing polymer.

20 19. A method of visualizing medical devices in magnetic resonance imaging, comprising coating the devices with a paramagnetic ion-containing polymer.




FIG. 1




FIG. 2

FIG. 3A





FIG. 3








FIG. 4



(a,b) Two temporal snapshots from a time series of 27 coronal images of a 6 French catheter filled with Gd-DTPA during movement through a static phantom. Scan parameters: TR = 4.6 msec, TE = 1.3 msec, acquisition matrix = 160×256 , reconstruction matrix = 256×256 , FOV = 20 cm \times 20 cm, slice thickness = 2 cm, flip angle = 40° , and temporal frame rate = 3 images/sec. Note that the background signal is very high because no projection dephaser was used. (c,d) Similar time frames to those shown in (a) and (b) except that the projection dephaser was enabled. Turning the projection dephaser on gives better background suppression.


FIG. 5



(a,b) Two time frames from a time series of 27 coronal images of a 6 French catheter filled with Gd-DTPA moving in the common carotid of a canine. Scan parameters: TR = 4.6 msec, TE = 1.3 msec, acquisition matrix = 160×256 , reconstruction matrix = 256×256 , FOV = 20 cm \times 20 cm, slice thickness = 2 cm, flip angle = 40° , and temporal frame rate = 3 images/sec. Enabling the projection dephaser (a,b) suppresses the background signal and makes the catheter more visible. (c,d) The same time frames as shown in (a) and (b) superimposed onto a previously acquired roadmap image.

FIG. 6

7/7



(a) A temporal snapshot of a 6 French catheter filled with Gd-DTPA in the canine aorta with the projection dephaser enabled. (b) The same time frame as in (a) after masking by an image at an earlier time frame. Scan parameters: TR = 4.6 msec, TE = 1.3 msec, acquisition matrix = 160×256 , reconstruction matrix = 256×256 , FOV = 20 cm \times 20 cm, slice thickness = 2 cm, flip angle = 40° , and temporal frame rate = 3 images/sec. The catheter images in (a) and (b) are shown superimposed onto a previously acquired roadmap image in (c) and (d), respectively, after zero-filling the catheter image by a factor of 2 in both readout and phase encoding directions.

FIG. 7


THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/00, A61L 29/00, A61M 25/00		A3	(11) International Publication Number: WO 99/60920
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11672		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 May 1999 (26.05.99)			
(30) Priority Data: 60/086,817 26 May 1998 (26.05.98) US 09/105,033 25 June 1998 (25.06.98) US			
(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; P.O. Box 7365, Madison, WI 53707-7365 (US).			
(72) Inventors: FRAYNE, Richard; 3712 Hillcrest Drive, Madison, WI 53705-5240 (US). STROTHER, Charles, M.; 6014 Greentree Road, Madison, WI 53711 (US). UNAL, Orhan; 3005 Prairie Road, Madison, WI 53719 (US). YANG, Zhihao; 305 H Eagle Height, Madison, WI 53705 (US). WEHELIE, Abukar; 230 Randolph Drive, 102C, Madison, WI 53717 (US). YU, Hyuk; 3183 Danhouser Road, Blue Mounds, WI 53517 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agents: WELCH, Teresa, J. et al.; Michael Best & Friedrich, LLP, Suite 700, One South Pinckney Street, Madison, WI 53701-1806 (US).		(88) Date of publication of the international search report: 6 April 2000 (06.04.00)	

(54) Title: MR SIGNAL-EMITTING COATINGS



(57) Abstract

The present invention provides a coating that emits magnetic resonance signals and a method for coating medical devices therewith. The coating includes a paramagnetic metal ion-containing polymer complex that facilitates diagnostic and therapeutic techniques by readily visualizing medical devices coated with the complex.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Internat. Application No.
PCT/US 99/11672

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K49/00 A61L29/00 A61M25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K A61L A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched —

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 08629 A (STERLING WINTHROP INC) 28 April 1994 (1994-04-28)	5,7,8,18
Y	examples 1-19	9-13
X	EP 0 331 616 A (SCHERING AG) 6 September 1989 (1989-09-06)	5,7,8,18
Y	page 44, line 40 - line 50 claim 4	9-13
X	WO 95 24225 A (NYCOMED SALUTAR INC ;COCKBAIN JULIAN R M (GB); MARGERUM LAWRENCE () 14 September 1995 (1995-09-14) page 45 page 50, line 12	9,11,12, 18
	— —/—	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 October 1999

Date of mailing of the international search report

28/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Trifillieff-Riolo, S

INTERNATIONAL SEARCH REPORT

Intern nal Application No
PCT/US 99/11672

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 00588 A (NYCOMED IMAGING AS ;COCKBAIN JULIAN R M (GB); LADD DAVID LEE (US)) 11 January 1996 (1996-01-11)	5-8, 18
Y	page 25, line 12 -page 30, line 27	9-13
X	US 4 986 980 A (JACOBSEN TROND) 22 January 1991 (1991-01-22) examples 26-28	5, 8, 18
A	FRIED ET AL: "image-guided surgery in a new magnetic resonance suite: preclinical considerations" LARYNGOSCOPE, vol. 106, no. 4, 1996, pages 411-417, XP002120474 the whole document	1-19

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter national Application No

PCT/US 99/11672

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9408629	A	28-04-1994	US 5756688 A	26-05-1998
			US 5817292 A	06-10-1998
			AU 5329194 A	09-05-1994
			CA 2146992 A	28-04-1994
			EP 0664714 A	02-08-1995
			JP 8502530 T	19-03-1998
EP 0331616	A	06-09-1989	DE 3806795 A	07-09-1989
			AT 130017 T	15-11-1995
			DE 58909479 D	21-12-1995
			GR 3018071 T	29-02-1996
			JP 2196864 A	03-08-1990
			JP 2685568 B	03-12-1997
			NO 174394 B	17-01-1994
			US 5681543 A	28-10-1997
			US 5681544 A	28-10-1997
WO 9524225	A	14-09-1995	AU 1852995 A	25-09-1995
			CA 2181070 A	14-09-1995
			CN 1139882 A	08-01-1997
			EP 0748229 A	18-12-1996
			JP 9510239 T	14-10-1997
WO 9600588	A	11-01-1996	US 5958372 A	28-09-1999
			AU 2799695 A	25-01-1996
			CA 2191878 A	11-01-1996
			CN 1151702 A	11-06-1997
			EP 0767679 A	16-04-1997
			JP 9507876 T	12-08-1997
US 4986980	A	22-01-1991	SE 465907 B	18-11-1991
			AT 54416 T	15-07-1990
			DK 499985 A	02-05-1986
			EP 0186947 A	09-07-1986
			JP 1937491 C	09-06-1995
			JP 6067854 B	31-08-1994
			JP 61155337 A	15-07-1986
			SE 8405499 A	02-05-1986

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)